A phase 1b study of GemRIS (TAR-200) in combination with nivolumab (Opdivo) in patients with Muscle Invasive Bladder Cancer (MIBC).
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 26 Dec 2017 New trial record